NSE / BSEHealthcare
β‚Ή860.10-2.05-0.24%
P/E52.6Mkt Capβ‚Ή5.77 K CrEV/EBITDA53.7

Shilpa Medicare Ltd.

P/E52.6Mkt Capβ‚Ή5.77 K CrEV/EBITDA53.7
Company Profile

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 26 Aug 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 108.90% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+12.1%); Jan the lowest (-5.6%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-9.7%Negative MonthJan 2026: -9.73%+16.0%Positive MonthFeb 2026: +15.99%+3.7%Positive MonthMar 2026: +3.67%+16.7%Positive MonthApr 2026: +16.71%+22.4%Positive MonthMay 2026: +22.43%+20.2%Positive MonthJun 2026: +20.15%+2.5%Positive MonthJul 2026: +2.53%+40.1%*Positive MonthAug 2026: +40.15%β€”β€”β€”β€”
2025-13.0%Negative MonthJan 2025: -13.02%-14.1%Negative MonthFeb 2025: -14.11%+8.7%Positive MonthMar 2025: +8.72%-2.5%Negative MonthApr 2025: -2.53%+39.3%Positive MonthMay 2025: +39.29%-2.0%Neutral MonthJun 2025: -1.97%+0.1%Neutral MonthJul 2025: +0.15%-4.2%Negative MonthAug 2025: -4.23%-10.9%Negative MonthSep 2025: -10.86%-6.1%Negative MonthOct 2025: -6.09%-3.5%Negative MonthNov 2025: -3.51%-6.0%Negative MonthDec 2025: -6.03%
2024+11.4%Positive MonthJan 2024: +11.37%+13.4%Positive MonthFeb 2024: +13.36%+10.6%Positive MonthMar 2024: +10.61%+19.4%Positive MonthApr 2024: +19.37%-12.0%Negative MonthMay 2024: -11.96%+17.5%Positive MonthJun 2024: +17.47%+19.8%Positive MonthJul 2024: +19.76%+12.6%Positive MonthAug 2024: +12.60%+5.9%Positive MonthSep 2024: +5.91%+3.6%Positive MonthOct 2024: +3.55%+6.7%Positive MonthNov 2024: +6.70%-9.2%Negative MonthDec 2024: -9.17%
2023-11.5%Negative MonthJan 2023: -11.50%+4.4%Positive MonthFeb 2023: +4.39%-10.8%Negative MonthMar 2023: -10.78%+11.9%Positive MonthApr 2023: +11.93%-6.8%Negative MonthMay 2023: -6.76%+18.9%Positive MonthJun 2023: +18.88%+24.9%Positive MonthJul 2023: +24.92%+4.0%Positive MonthAug 2023: +4.01%-3.0%Negative MonthSep 2023: -3.04%-1.1%Neutral MonthOct 2023: -1.10%+2.9%Positive MonthNov 2023: +2.93%-9.5%Negative MonthDec 2023: -9.45%
2022-5.3%Negative MonthJan 2022: -5.33%-19.9%Negative MonthFeb 2022: -19.88%-2.3%Negative MonthMar 2022: -2.34%+15.2%Positive MonthApr 2022: +15.20%-5.2%Negative MonthMay 2022: -5.25%-10.4%Negative MonthJun 2022: -10.39%+6.3%Positive MonthJul 2022: +6.29%-4.7%Negative MonthAug 2022: -4.73%-1.8%Neutral MonthSep 2022: -1.78%-18.4%Negative MonthOct 2022: -18.44%-10.6%Negative MonthNov 2022: -10.65%-1.2%Neutral MonthDec 2022: -1.17%
2021β€”β€”β€”β€”β€”+4.5%Positive MonthJun 2021: +4.47%+17.2%Positive MonthJul 2021: +17.18%-8.8%Negative MonthAug 2021: -8.77%-3.5%Negative MonthSep 2021: -3.47%+4.8%Positive MonthOct 2021: +4.83%-6.7%Negative MonthNov 2021: -6.66%-1.6%Neutral MonthDec 2021: -1.55%
AvgΒ±SD-5.6%Β±8.9%-0.1%Β±14.5%+2.0%Β±7.8%+12.1%Β±7.7%+7.6%Β±19.9%+8.1%Β±11.6%+11.8%Β±9.3%+6.5%Β±16.6%-2.6%Β±5.3%-3.4%Β±8.4%-2.2%Β±6.3%-5.5%Β±3.6%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 2.678x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή476.00 Crβ–² 53.5%
EBITDA Growthβ€”
Net Profitβ‚Ή70.00 Crβ–² 159.3%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 100.0%
Revenue CAGR 5Y-17.4%
EBITDA CAGR 5Y-17.6%
Net Profit CAGR 5Y-32.6%
NP Growth 1Y159.3%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή476.00 Crβ€”β‚Ή70.00 Crβ€”β€”2.6%53.5%159.3%
Mar 2024β‚Ή310.00 Crβ€”β‚Ή27.00 Crβ€”β€”1.3%25.0%-52.6%
Mar 2023β‚Ή248.00 Crβ€”β‚Ή57.00 Crβ€”β€”2.7%-30.5%-59.6%
Mar 2022β‚Ή357.00 Crβ€”β‚Ή141.00 Crβ€”β€”6.8%38.9%-23.4%
Mar 2021β‚Ή257.00 Crβ€”β‚Ή184.00 Crβ€”β€”11.2%-68.1%-5.2%
Mar 2020β‚Ή806.00 Crβ€”β‚Ή194.00 Crβ€”β€”13.4%21.4%56.5%
Mar 2019β‚Ή664.00 Crβ€”β‚Ή124.00 Crβ€”β€”9.7%-10.4%-6.8%
Mar 2018β‚Ή741.00 Crβ€”β‚Ή133.00 Crβ€”β€”11.5%1.0%4.7%
Mar 2017β‚Ή734.00 Crβ€”β‚Ή127.00 Crβ€”β€”12.3%8.6%12.4%
Mar 2016β‚Ή676.00 Crβ€”β‚Ή113.00 Crβ€”β€”17.0%19.6%34.5%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales527565676734741664806257357248310476479
Total Expenses410429511551562487561223335291284353365
EBIT / Operating Profit1181371641831791772453422-4426123113
OPM %22%24%24%25%24%27%30%13%6%-18%8%26%24%
Other Income95915232132204170159793914
Finance Costs343323469211778
Depreciation & Amortisation21192127333435223547504950
Profit Before Tax102119149169167162238210148483810769
Tax %21%29%24%24%20%23%19%12%5%-18%29%35%-
Net Profit / PAT818411312713312419418414157277062
EPS (β‚Ή)5.495.457.327.958.177.6111.8811.318.123.291.553.573.17
Dividend Payout %5%5%4%4%4%7%5%5%7%0%0%14%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Shilpa Medicare Ltd.this co.β‚Ή5.77 K Crβ‚Ή476.00 Cr52.602.1553.7553.5%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Shilpa Medicare Ltd. and the metrics that matter.

Browse the full Equiscale Academy